Introduction: A paucity of literature exists regarding current opioid prescribing and use following bariatric surgery. We aimed to characterize opioid prescribing practices and use following bariatric surgery to inform future studies and optimized prescribing practices.
Methods And Procedure: We performed a systematic review of Ovid MEDLINE, Ovid Embase, Scopus, Web of Science Core Collection, and Cochrane Library (via WILEY) on August 20, 2021. Two reviewers reviewed and extracted data independently. Studies evaluating adult patients undergoing bariatric surgery that reported opioid prescriptions at discharge were included. Abstracts, non-English studies, and those with n < 5 were excluded. Primary outcomes assessed the amount of morphine milligram equivalents (MMEs) prescribed at discharge. Secondary outcomes evaluated opioids used following discharge, proportion of patients with unused opioid, and if unused opioids were properly discarded.
Results: We evaluated 2113 studies, with 18 undergoing full-text review, and 5 meeting inclusion criteria. Overall, 847 patients were included, with 450 (53%) undergoing sleeve gastrectomy and 393 (46%) receiving Roux-en-Y gastric bypass. Most patients were female (n = 484/589, 82.2%), and the average age and BMI were 44.6 (± 11.8) years and 48.1 kg/m (± 8.4 kg/m), respectively. On average, 348.4 MMEs were prescribed to patients undergoing bariatric surgery. Patients used only 84.7 MMEs, with 87.0% (95% CI 66.0-99.0%) having unused opioid, and 41/120 (34.2%) retaining these excess opioids.
Conclusion: Nearly 90% of all bariatric patients evaluated in our systematic review are prescribed excessive opioids at discharge. Further work characterizing current opioid prescribing practices and use may help guide development of standardized post-bariatric surgery prescription guidelines.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00464-022-09481-7 | DOI Listing |
Orv Hetil
January 2025
1 Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház-Rendelőintézet, Általános-Mellkassebészeti Osztály Szolnok Magyarország.
Surg Obes Relat Dis
December 2024
UMass Memorial Medical Center, Worcester, Massachusetts.
Surg Obes Relat Dis
December 2024
Department of Digestive Surgery, Magellan Center, Bordeaux University Hospital Pessac, Bordeaux, France; BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, Univ. Bordeaux, Bordeaux, France. Electronic address:
Background: The risk of esophageal cancer after bariatric surgery is a matter of debate.
Objective: This study aims to evaluate the risk of esophageal cancer following sleeve gastrectomy (SG) and gastric bypass (GB).
Methods: We extracted data from the national discharge database (Programme De Médicalisation des Systèmes d'Information) for patients who underwent bariatric surgery in France between 2007 and 2020.
Surg Obes Relat Dis
December 2024
Northwestern Quality Improvement, Research and Education in Surgery, Northwestern University, Feinberg School of Medicine, Chicago, Illinois; Division of General Internal Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Background: Utilization of metabolic and bariatric surgery has increased significantly over the last 2decades, yet barriers to access remain.
Objectives: This study aimed to 1) define rates of metabolic and bariatric surgery utilization for qualifying adults in Illinois and 2) describe patient characteristics associated with undergoing surgery at Illinois hospitals with low metabolic and bariatric surgery volume.
Setting: Metabolic and bariatric surgery at all nonfederal Illinois hospitals was included.
Obes Surg
January 2025
Division of Upper Gastrointestinal and General Surgery, Department of Surgery, Keck Medical Center of University of Southern California, Los Angeles, USA.
Background: Bariatric surgery is the most effective intervention for severe pediatric obesity, but a subset of youth experience suboptimal weight loss and/or recurrent weight gain. Early re-initiation of obesity pharmacotherapy postoperatively may improve outcomes, though this has not been evaluated in pediatric populations.
Methods: A retrospective cohort study at a tertiary care children's hospital evaluated the safety and efficacy of reintroducing obesity pharmacotherapy within six weeks after laparoscopic sleeve gastrectomy (LSG).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!